KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Deferred Taxes (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Deferred Taxes for 9 consecutive years, with -$595.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes fell 1959.38% year-over-year to -$595.0 million, compared with a TTM value of -$671.0 million through Dec 2025, down 5.84%, and an annual FY2025 reading of -$671.0 million, down 5.84% over the prior year.
  • Deferred Taxes was -$595.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $107.0 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $150.0 million in Q4 2022 and bottomed at -$1.1 billion in Q2 2022.
  • Average Deferred Taxes over 5 years is -$140.3 million, with a median of -$48.5 million recorded in 2023.
  • Peak annual rise in Deferred Taxes hit 450.0% in 2022, while the deepest fall reached 6868.75% in 2022.
  • Year by year, Deferred Taxes stood at -$133.0 million in 2021, then skyrocketed by 212.78% to $150.0 million in 2022, then plummeted by 78.67% to $32.0 million in 2023, then changed by 0.0% to $32.0 million in 2024, then crashed by 1959.38% to -$595.0 million in 2025.
  • Business Quant data shows Deferred Taxes for TEVA at -$595.0 million in Q4 2025, $107.0 million in Q3 2025, and -$211.0 million in Q2 2025.